Potential therapeutic targets in sarcomas include vascular endothelial growth factor (VEGFR), platelet-derived growth factor receptor (PDGFR), insulin-like growth factor receptor, cellular receptor tyrosine kinase KIT (KIT), fibroblast growth factor receptor (FGFR), mesenchymal-epithelial transition (MET) and AXL receptor tyrosine kinase (AXL) [22]. The gene discussed is MET; the disease is sarcoma.